Angela Carvalho
Co-Founder & Chief Executive Officer Beat Therapeutics
Seminars
Wednesday 28th January 2026
Expanding the DDR Target Landscape: Therapeutic Potential of BRCA1-Mediated Pathways
12:00 pm
• See how Beat Therapeutics is targeting BRCA1-mediated pathways with a first-in-class small molecule
• Highlighting BRCA1-BARD1 disruption, which impacts downstream repair pathways and presents synergistic potential with standard-of-care therapies
• Investigating the therapeutic potential of BRCA1 inhibition to restore sensitivity in resistant cancers
